Cereno Scientific activates first site for Phase IIb EPIMODE trial of CS1 in pulmonary arterial hypertension

• Cereno Scientific activated the first clinical site in its global Phase IIb EPIMODE trial of CS1 in pulmonary arterial hypertension, opening patient screening.
• No results were presented; top-line data are expected in Q4 2028 based on the planned recruitment timeline.
• The study will test whether CS1 can improve disease status when added to standard care, building on earlier encouraging safety and activity signals.
• The trial is designed to support dose selection and assess potential disease-modifying effects, a key step toward later-stage development and partnering.
• The company cited a SEK 60 million directed share issue, strengthening funding flexibility as the trial moves toward first dosing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cereno Scientific AB published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.